ORIC Pharmaceuticals’ (ORIC) Overweight Rating Reiterated at Cantor Fitzgerald

ORIC Pharmaceuticals (NASDAQ:ORIC)‘s stock had its “overweight” rating reiterated by stock analysts at Cantor Fitzgerald in a note issued to investors on Monday, Benzinga reports.

Other analysts also recently issued research reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of ORIC Pharmaceuticals in a research report on Wednesday, September 18th. Oppenheimer dropped their price objective on ORIC Pharmaceuticals from $17.00 to $15.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 13th. Wedbush reissued an “outperform” rating and issued a $20.00 price objective on shares of ORIC Pharmaceuticals in a report on Tuesday, September 10th. Finally, Stifel Nicolaus assumed coverage on shares of ORIC Pharmaceuticals in a report on Friday, September 6th. They set a “buy” rating and a $20.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $18.00.

ORIC Pharmaceuticals Stock Up 0.2 %

NASDAQ:ORIC opened at $10.75 on Monday. ORIC Pharmaceuticals has a twelve month low of $5.27 and a twelve month high of $16.65. The company has a market cap of $724.79 million, a P/E ratio of -5.97 and a beta of 1.12. The business has a 50 day moving average price of $10.06 and a two-hundred day moving average price of $9.88.

ORIC Pharmaceuticals (NASDAQ:ORIC) last released its earnings results on Monday, August 12th. The company reported ($0.45) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.03). As a group, analysts anticipate that ORIC Pharmaceuticals will post -1.78 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of ORIC Pharmaceuticals by 162.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,152 shares of the company’s stock valued at $36,000 after acquiring an additional 3,188 shares in the last quarter. Quest Partners LLC raised its holdings in shares of ORIC Pharmaceuticals by 253.2% during the 2nd quarter. Quest Partners LLC now owns 10,378 shares of the company’s stock worth $73,000 after buying an additional 7,440 shares in the last quarter. XTX Topco Ltd acquired a new position in ORIC Pharmaceuticals during the second quarter worth about $153,000. Cornercap Investment Counsel Inc. bought a new position in ORIC Pharmaceuticals in the 2nd quarter valued at approximately $154,000. Finally, Profund Advisors LLC boosted its holdings in shares of ORIC Pharmaceuticals by 23.6% during the 2nd quarter. Profund Advisors LLC now owns 21,861 shares of the company’s stock valued at $155,000 after acquiring an additional 4,175 shares in the last quarter. 95.05% of the stock is owned by institutional investors.

About ORIC Pharmaceuticals

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.